NCT02513121

Brief Summary

This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU). The purpose of this study is to understand the potential of a low sugar diet for the treatment of nonalcoholic fatty liver disease (NAFLD) in children. Forty boys with NAFLD will be randomly assigned to either an intervention group or a habitual diet control group. The intervention will be a low sugar diet for a period of 8 weeks. The effect of this dietary change will be assessed using advanced magnetic resonance imaging (MRI) testing to measure liver fat.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2015

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

July 29, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 31, 2015

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2017

Completed
2.4 years until next milestone

Results Posted

Study results publicly available

January 28, 2020

Completed
Last Updated

January 28, 2020

Status Verified

January 1, 2020

Enrollment Period

2.2 years

First QC Date

July 29, 2015

Results QC Date

June 26, 2019

Last Update Submit

January 16, 2020

Conditions

Keywords

NAFLDSteatohepatitisNonalcoholic Steatohepatitis (NASH)LiverDietPediatricAdolescent

Outcome Measures

Primary Outcomes (1)

  • Change in Percentage of Liver Fat Measured by Magnetic Resonance Imaging (MRI) in the Intervention Group Compared to Change in the Control Group

    The principal objective of this randomized and controlled pilot study is to evaluate whether 8 weeks of a low added sugar diet (\<3%) in boys with NAFLD will change liver fat % measured by MRI.

    Measurements done at baseline and week 8.

Secondary Outcomes (6)

  • Change in Alanine Aminotransferase (ALT) From Baseline to Week 8

    Measurements done at baseline and week 8

  • Change in Aspartate Aminotransferase (AST) From Baseline to Week 8

    Measurements doen at baseline and week 8

  • Change in Gamma-Glutamyl Transpeptidase (GGT) From Baseline to Week 8

    Measurements done at baseline and week 8

  • Change in Insulin From Baseline to Week 8

    Measurements done at baseline and week 8

  • Change in Homeostasis Model Assessment- Insulin Resistance (HOMA-IR) From Baseline to Week 8

    Measurements done at baseline and week 8

  • +1 more secondary outcomes

Study Arms (2)

Dietary modification

ACTIVE COMPARATOR

Low free sugar diet

Other: Dietary modification

Observational Arm

NO INTERVENTION

Standard of care

Interventions

The intervention is a modification of the family's habitual diet with a low sugar version of their diet.

Dietary modification

Eligibility Criteria

Age11 Years - 16 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Boys age 11-16 years inclusive.
  • Clinical history consistent with NAFLD.
  • Biopsy-proven NAFLD
  • MRI measured Liver Proton Density Fat Fraction ≥10%
  • alanine aminotransferase (ALT) ≥ 45 u/L
  • No evidence of any other liver disease by clinical history or histological evaluation.
  • Written informed consent from parent or legal guardian.
  • Written informed assent from the child or adolescent.

You may not qualify if:

  • History of significant alcohol intake (Alcohol Use Disorders Identification Test \[AUDIT\]) or inability to quantify alcohol consumption
  • Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis in the past year.
  • The use of other known hepatotoxins within 120 days of baseline
  • History of total parenteral nutrition (TPN) use in the year prior to screening
  • History of bariatric surgery or planning to undergo bariatric surgery during the study duration
  • Significant depression
  • Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:
  • Hemoglobin \< 10 g/dL
  • White blood cell \< 3,500 cells/mm
  • Neutrophil count \< 1,500 cells/mm3 of blood
  • Platelets \< 130,000 cells/mm3 of blood
  • Direct bilirubin \> 1.0 mg/dL
  • Total bilirubin \> 3 mg/dL
  • Albumin \< 3.2 g/dL
  • International normalized ratio (INR) \> 1.4
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of California, San Diego

San Diego, California, 92093, United States

Location

Emory University

Atlanta, Georgia, 30322, United States

Location

Related Publications (9)

  • Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003 Oct;143(4):500-5. doi: 10.1067/S0022-3476(03)00325-1.

    PMID: 14571229BACKGROUND
  • Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006 Oct;118(4):1388-93. doi: 10.1542/peds.2006-1212.

    PMID: 17015527BACKGROUND
  • Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008 Jul 15;118(3):277-83. doi: 10.1161/CIRCULATIONAHA.107.739920. Epub 2008 Jun 30.

    PMID: 18591439BACKGROUND
  • Jin R, Le NA, Liu S, Farkas Epperson M, Ziegler TR, Welsh JA, Jones DP, McClain CJ, Vos MB. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab. 2012 Jul;97(7):E1088-98. doi: 10.1210/jc.2012-1370. Epub 2012 Apr 27.

    PMID: 22544914BACKGROUND
  • Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, Vos MB. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014 Aug 8;6(8):3187-201. doi: 10.3390/nu6083187.

    PMID: 25111123BACKGROUND
  • Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015 Jun;61(6):1887-95. doi: 10.1002/hep.27666. Epub 2015 Feb 5.

    PMID: 25529941BACKGROUND
  • Jin R, Vos MB. Fructose and liver function--is this behind nonalcoholic liver disease? Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):490-5. doi: 10.1097/MCO.0000000000000203.

    PMID: 26203597BACKGROUND
  • Cohen CC, Li KW, Alazraki AL, Beysen C, Carrier CA, Cleeton RL, Dandan M, Figueroa J, Knight-Scott J, Knott CJ, Newton KP, Nyangau EM, Sirlin CB, Ugalde-Nicalo PA, Welsh JA, Hellerstein MK, Schwimmer JB, Vos MB. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021 Dec 15;131(24):e150996. doi: 10.1172/JCI150996.

  • Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow KE, Alazraki A, Durelle J, Knight-Scott J, Newton KP, Cleeton R, Knott C, Konomi J, Middleton MS, Travers C, Sirlin CB, Hernandez A, Sekkarie A, McCracken C, Vos MB. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019 Jan 22;321(3):256-265. doi: 10.1001/jama.2018.20579.

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseaseFatty Liver

Interventions

Diet Therapy

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Nutrition TherapyTherapeutics

Results Point of Contact

Title
Dr. Jeffrey Schwimmer
Organization
University of California, San Diego

Study Officials

  • Jeffrey B Schwimmer, MD

    University of California, San Diego

    PRINCIPAL INVESTIGATOR
  • Miriam Vos, MD

    Emory University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Pediatrics

Study Record Dates

First Submitted

July 29, 2015

First Posted

July 31, 2015

Study Start

July 1, 2015

Primary Completion

August 31, 2017

Study Completion

August 31, 2017

Last Updated

January 28, 2020

Results First Posted

January 28, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will share

De-identified participant data will be made available in response to bona fide and good faith, ad hoc requests. Suitability of each request, if consistent with Institutional Review Board (IRB) approval, will be determined only in the case of a favorable vote of a majority of a committee consisting of each consortium investigator and the Grantor. Data will be made available with a signed access agreement.

Locations